{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:48Z","timestamp":1786118868747,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/wnf.0b013e3180986d43","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T03:01:05Z","timestamp":1206414065000},"page":"86-92","source":"Crossref","is-referenced-by-count":31,"title":["Evaluation of Open-Label Topiramate as Primary or Adjunctive Therapy in Infantile Spasms"],"prefix":"10.1097","volume":"31","author":[{"given":"Li-Ping","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Cheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilhard","family":"Mix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0887-8994(00)00238-1","article-title":"Infantile spasms.","volume":"24","author":"Wong","year":"2001","journal-title":"Pediatr Neurol"},{"key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0387-7604(01)00312-6","article-title":"How do the many etiologies of infantile spasms lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis.","volume":"23","author":"Brunson","year":"2001","journal-title":"Brain Dev"},{"key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms.","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1212\/WNL.52.8.1713","article-title":"Visual field constriction in children treated with vigabatrin.","volume":"52","author":"Vanhatalo","year":"1999","journal-title":"Neurology"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1528-1157.1999.tb00780.x","article-title":"Topiramate pharmacokinetics in infants.","volume":"40","author":"Glauser","year":"1999","journal-title":"Epilepsia"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1111\/j.1528-1157.2000.tb02180.x","article-title":"Long-term response to topiramate in patients with infantile spasms.","volume":"41","author":"Glauser","year":"2000","journal-title":"Epilepsia"},{"key":"R7-4-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00128072-200103040-00006","article-title":"Topiramate: a review of its use in childhood epilepsy.","volume":"3","author":"Ormrod","year":"2001","journal-title":"Paediatr Drugs"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0387-7604(01)00312-6","article-title":"How do the many etiologies of Infantile spasms lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis.","volume":"23","author":"Brunson","year":"2001","journal-title":"Brain Dev"},{"key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.WNF.0000236768.54150.8C","article-title":"Prospective study of first-choice topiramate therapy in newly-diagnosed infantile spasms.","volume":"29","author":"Zou","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"R10-4-20210203","first-page":"31","article-title":"Immunologic aspects of topiramate treatment in Infantile spasms patients.","volume":"8","author":"Zou","year":"2003","journal-title":"HK J Pediatr"},{"key":"R11-4-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/08830738060210011001","article-title":"Topiramate for the treatment of infantile spasms.","volume":"21","author":"Hosain","year":"2006","journal-title":"J Child Neurol"},{"key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-1211(97)00045-4","article-title":"Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold.","volume":"28","author":"White","year":"1997","journal-title":"Epilepsy Res"},{"key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/08830738030180040901","article-title":"Clinical experience with open-label topiramate use in infants younger than 2 years of age.","volume":"18","author":"Watemberg","year":"2003","journal-title":"J Child Neurol"},{"key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00415-004-0344-0","article-title":"Drug selection for the newly diagnosed patient: when is a new generation antiepileptic drug indicated?","volume":"251","author":"Tomson","year":"2004","journal-title":"J Neurol"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1177\/0883073800015001S05","article-title":"Safety and tolerability of topiramate in children.","volume":"15","author":"Levisohn","year":"2000","journal-title":"J Child Neurol"},{"key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1111\/j.1528-1157.2000.tb02178.x","article-title":"Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures.","volume":"41","author":"Ritter","year":"2000","journal-title":"Epilepsia"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1177\/0883073800015001S05","article-title":"Safety and tolerability of topiramate in children.","volume":"15","author":"Levisohn","year":"2000","journal-title":"J Child Neurol"},{"key":"R18-4-20210203","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.1528-1157.2002.37201.x","article-title":"Topiramate and metabolic acidosis in infants and toddlers.","volume":"43","author":"Philippi","year":"2002","journal-title":"Epilepsia"},{"key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1528-1157.2001.04500.x","article-title":"Topiramate and metabolic acidosis in pediatric epilepsy.","volume":"42","author":"Takeoka","year":"2001","journal-title":"Epilepsia"},{"key":"R20-4-20210203","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2006.07.003","article-title":"Biochemical and stone-risk profiles with topiramate treatment.","volume":"48","author":"Welch","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R21-4-20210203","first-page":"58","article-title":"New antiepileptic agents.","volume":"26","author":"Nelson","year":"2004","journal-title":"Pediatr Dent"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-200803000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:55:28Z","timestamp":1786035328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200803000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3180986d43","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}